Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (83,984)	$ (72,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	531	117
Research and development license expense	1,250	5,500
Stock-based compensation	9,470	8,143
Other	387	194
Changes in operating assets and liabilities:
Prepaid expenses and other assets	80	(3,282)
Accounts payable	6,212	2,382
Accrued expenses and other liabilities	(7,958)	15,053
Due to related party		(8)
Net cash used in operating activities	(74,012)	(44,851)
Cash flows from investing activities
Purchase of research and development license	(3,250)	(5,500)
Purchase of property, plant and equipment	(16,290)	(3,532)
Net cash used in investing activities	(19,540)	(9,032)
Cash flows from financing activities
Payment of shelf registration costs	(227)
ESPP contributions	321
Proceeds from issuance of common stock, net of sales commissions	11,640
Other	(1,046)
Net cash provided by financing activities	10,688
Net decrease in cash, cash equivalents and restricted cash	(82,864)	(53,883)
Cash, cash equivalents and restricted cash at the beginning of the period	151,740	251,253
Cash, cash equivalents and restricted cash at the end of the period	68,876	197,370
Cash and cash equivalents	66,239	197,370
Restricted cash	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	935
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	2,722	3,308
Acquisition of property, plant and equipment funded by landlord		606
Deferred offering costs not yet paid	109
Purchase of research and development license not yet paid	$ 1,000
Build-to-suit lease liability		$ 26,250